99mTc-Radiolabelled Peptides for Tumour Imaging: Present and Future
- 1 August 2010
- journal article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 17 (24) , 2656-2683
- https://doi.org/10.2174/092986710791859388
Abstract
Abstract: Receptor-binding peptides have attracted an enormous interest in targeting molecules for the development of tumour specific radiopharmaceutical compounds. The overexpression of many receptors on human tumour makes such peptide-ligands attractive agents for diagnostic imaging and therapy of cancers. The use of solid-phase peptide synthesis and the availability of a wide range of bifunctional chelating agents for the radiolabelling of bioactive peptides with radionuclides have produced a wide variety of useful radiopharmaceutical molecules. For diagnostic purposes, techenetium- 99m is the ideal radionuclide thanks to its nuclear properties and the availability of a low cost portable generator system.Keywords
This publication has 0 references indexed in Scilit: